Back to results
US 2025/0145588 A1Published application
Crystal form of tavapadon, and preparation method therefor and use thereof
AssigneeCrystal Pharmaceutical (Suzhou) Co., Ltd.
InventorsHaiyan QIN, Jiaming SHI
Life of this patent
Estimating the term…
Abstract
A novel crystalline form of Tavapadon (hereinafter referred to as “Compound I”) and its preparation method, pharmaceutical compositions containing this crystalline form, and its use in the preparation of dopamine D1/D5 receptor agonist drugs and in the treatment of Parkinson's disease. The crystalline form of Compound I provided by the present disclosure has one or more improved properties compared to prior arts, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
Claims9
1-5. (canceled)
A crystalline form of Compound I
- wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2theta values of 7.8°±0.2°, 15.1°±0.2° and 17.0°±0.2° using Cu-Kα radiation.
Dependencies are inferred from the claim text.